Clarity Pharmaceuticals Reports Promising Results in Prostate Cancer Trial

MT Newswires Live10-16

Clarity Pharmaceuticals (ASX:CU6) said its SECuRE trial for the radiopharmaceutical 67Cu-SAR-bisPSM reported favorable safety profiles and reductions in prostate-specific antigen (PSA) levels.

Preliminary efficacy data showed all three participants had lower PSA levels, with the largest decrease at nearly 96%, according to a Wednesday filing with the Australian bourse.

While no dose-limiting toxicity was observed, a patient experienced moderate nausea that was resolved.

Clarity Pharmaceuticals said it allocated three more slots in its multi-dose trial, with two participants receiving their first cycle of 12GBq of 67Cu-SAR-bisPSMA. The last participant has started screening activities and is scheduled to receive his first therapy cycle in the coming weeks.

Shares of the pharmaceutical company were down nearly 2% in recent Wednesday trade.

Price (AUD): $6.70, Change: $-0.11, Percent Change: -1.62%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475230806?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-16 09:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475230806","market":"hk","top_or_hot":-1,"title":"Clarity Pharmaceuticals Reports Promising Results in Prostate Cancer Trial","media":"MT Newswires Live","content":"<html><body><p> Clarity Pharmaceuticals (ASX:CU6) said its SECuRE trial for the radiopharmaceutical 67Cu-SAR-bisPSM reported favorable safety profiles and reductions in prostate-specific antigen (PSA) levels.</p><p>Preliminary efficacy data showed all three participants had lower PSA levels, with the largest decrease at nearly 96%, according to a Wednesday filing with the Australian bourse.</p><p>While no dose-limiting toxicity was observed, a patient experienced moderate nausea that was resolved.</p><p>Clarity Pharmaceuticals said it allocated three more slots in its multi-dose trial, with two participants receiving their first cycle of 12GBq of 67Cu-SAR-bisPSMA. The last participant has started screening activities and is scheduled to receive his first therapy cycle in the coming weeks.</p><p>Shares of the pharmaceutical company were down nearly 2% in recent Wednesday trade.</p><p>Price (AUD): $6.70, Change: $-0.11, Percent Change: -1.62%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clarity Pharmaceuticals Reports Promising Results in Prostate Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClarity Pharmaceuticals Reports Promising Results in Prostate Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-16 09:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Clarity Pharmaceuticals (ASX:CU6) said its SECuRE trial for the radiopharmaceutical 67Cu-SAR-bisPSM reported favorable safety profiles and reductions in prostate-specific antigen (PSA) levels....</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSA","symbol_name":"公共存储公司","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2475230806","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475230806","pubTimestamp":1729042915,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clarity Pharmaceuticals (ASX:CU6) said its SECuRE trial for the radiopharmaceutical 67Cu-SAR-bisPSM reported favorable safety profiles and reductions in prostate-specific antigen (PSA) levels.Prelimin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PSA":"公共存储公司","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4125":"广播","BK7096":"制药","BK4585":"ETF&股票定投概念","BK4084":"特种房地产投资信托","BK4588":"碎股","AUD":"Audacy Inc.","BK4217":"自存仓储房地产信托","CU6.AU":"CLARITY PHARMACEUTICALS LTD"},"translate_title":"Clarity Pharmaceuticals报告前列腺癌试验取得有希望的结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"PSA":1,"CU6.AU":0.9},"content_text":"Clarity Pharmaceuticals (ASX:CU6) said its SECuRE trial for the radiopharmaceutical 67Cu-SAR-bisPSM reported favorable safety profiles and reductions in prostate-specific antigen (PSA) levels.Preliminary efficacy data showed all three participants had lower PSA levels, with the largest decrease at nearly 96%, according to a Wednesday filing with the Australian bourse.While no dose-limiting toxicity was observed, a patient experienced moderate nausea that was resolved.Clarity Pharmaceuticals said it allocated three more slots in its multi-dose trial, with two participants receiving their first cycle of 12GBq of 67Cu-SAR-bisPSMA. The last participant has started screening activities and is scheduled to receive his first therapy cycle in the coming weeks.Shares of the pharmaceutical company were down nearly 2% in recent Wednesday trade.Price (AUD): $6.70, Change: $-0.11, Percent Change: -1.62%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475230806"}